Ravault A, Meunier P J
Service de Rhumatologie et Pathologie Osseuse, Hôpital Edouard-Herriot, Lyon.
Rev Rhum Mal Osteoartic. 1989 Mar 15;56(4):293-302.
987 patients with Paget's disease were treated with disodium etidronate at an oral dose of 5 mg/kg/d and followed up for an average of 5.2 years: each course of treatment lasted 6 months and was repeated once or several times. 76 per cent of the patients with symptoms had improved by the end of the follow up period, and 85 per cent of the asymptomatic patients showed none of the complications that might have been expected preventive treatment with etidronate not been undertaken. The course of the disease deteriorated in 28% of the patients between start and finish of the study, but the result was sometimes incomplete or in some doubt. For patients receiving treatment, the annual incidence of coxarthropathy was 1 per cent. In patients with medullary involvement, indicated by spasmodic paraparesis during the initial assessment, oral disodium etidronate always had a curative effect. In patients with cranial involvement, the condition worsened fairly frequently, with hypoacusis arising or deteriorating in 29 per cent of the patients. Twenty three fractures occurred, including 8 in pagetic bone, with an incidence of respectively 5 and 1.7 per cent patient-years: the risk of fracture did not seem to be increased when etidronate was used at a low dose. Among the side effects observed, there was a delayed increase in bone pain in 12.5 per cent of the patients, the symptoms generally resolving except in one case where a fracture occurred.(ABSTRACT TRUNCATED AT 250 WORDS)
987例佩吉特病患者接受了依替膦酸二钠治疗,口服剂量为5mg/kg/天,平均随访5.2年:每个疗程持续6个月,重复一次或多次。76%有症状的患者在随访期末病情有所改善,85%无症状的患者未出现若未进行依替膦酸预防性治疗可能会出现的并发症。在研究开始至结束期间,28%的患者病情恶化,但结果有时不完全或存在一定疑问。接受治疗的患者中,髋关节炎的年发病率为1%。对于初始评估时有痉挛性截瘫提示有髓内受累的患者,口服依替膦酸二钠始终具有治愈效果。对于有颅骨受累的患者,病情相当频繁地恶化,29%的患者出现听力减退或听力减退加重。发生了23例骨折,其中8例发生在佩吉特骨,发病率分别为每患者年5%和1.7%:低剂量使用依替膦酸时骨折风险似乎并未增加。在观察到的副作用中,12.5%的患者出现骨痛延迟加重,除1例发生骨折的情况外,症状一般会缓解。(摘要截选至250字)